CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population

Cancer Epidemiology

Volumn 35, Issue 5, 2011, Pages 480-484

  Souiden, Yousra ^a,b   Mahdouani, Manel ^a   Chaieb, Kamel ^b   Elkamel, Rafik ^a   Mahdouani, Kacem ^a,b  

^a Hospital of Ibn Eljazzar of Kairouan   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

CYP17; Polymorphism; Prostate cancer; Tunisian population

Indexed keywords

CYTOCHROME P450 17;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DNA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; TUMOR MARKERS, BIOLOGICAL; TUNISIA;

EID: 80052937355     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2010.11.008     Document Type: Article

References (60)

1. Bosland M.C. Animal models for the study of prostate carcinogenesis. J Cell Biochem 1992, 16H:89-98.
2. Gann P.H., Hennekens C.H., Ma J., Longcope C., Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88:1118-1126.
3. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Staczyk F.Z., Henderson B.E. Cytochrome P350c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998, 58:585-587.
4. Ross R.K., Coetzee G.A., Pearce C.L., Reihardt J.K., Bretsky P., Kolonel L.N., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Eur Urol 1999, 35:355-361.
5. Bosland M.C. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000, 27:39-66.
6. Hsing A.W., Reichardt J.K., Stanczyk F.Z. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002, 52(3):213-235.
7. Platz E.A., Giovannucci E. The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 2004, 92(4):237-253.
8. Bostwick D.G., Burke H.B., Djakiew D., Euling S., Ho S.M., Landolph J., et al. Human prostate cancer risk factors. Cancer 2004, 101(10):2371-2490.
9. Ozasa K., Nakao M., Watanabe Y., Hayashi K., Miki T., Mikami K., et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004, 95(1):65-71.
10. Platz E.A., Leitzmann M.F., Rifai N., Kantoff P.W., Chen Y.C., Stampfer M.J., et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1262-1269.
11. Severi G., Morris H.A., MacInnis R.J., English D.R., Tilley W., Hopper J.L., et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(1):86-91.
12. Travis R.C., Key T.J., Allen N.E., Appleby P.N., Roddam A.W., Rinaldi S., et al. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007, 121(6):1331-1338.
13. Weiss J.M., Huang W.Y., Rinaldi S., Fears T.R., Chatterjee N., Hsing A.W., et al. Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int J Cancer 2008, 122(10):2345-2350.
14. Wiren S., Stocks T., Rinaldi S., Hallmans G., Bergh A., Stenman U.H., et al. Androgens and prostate cancer risk: a prospective study. Prostate 2007, 67(11):1230-1237.
15. Roddam A.W., Allen N.E., Appleby P., Key T.J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Nat Cancer Inst 2008, 100(3):170-183.
16. Febbo P.G., Kantoff P.W., Platz E.A., Casey D., Batter S., Giovannucci E., et al. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer. Cancer Res 1999, 59:5878-5881.
17. Lunn R.M., Bell D.A., Mohler J.L., Taylor J.A. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999, 20:1727-1731.
18. Makridakis N., Ross R.K., Pike M.C., Crocitto L.E., Kolonel L.N., Pearce C.L., et al. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 2000, 354:975-978.
19. Platz E.A., Giovannucci E., Brown M., Cieluch C., Shepard T.F., Stampfer M.J., et al. Amplified in breast cancer 1 (AIB1) glutamine repeat and prostate cancer risk. Prostate J 2000, 2:27-32.
20. Ross R.K., Pike M.C., Coetzee G.A., Reichardt J.K.V., Yu M.C., Feigelson H., et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998, 58:4497-4504.
21. Wadelius M., Andersson S.-O., Johansson J.-E., Wadelius C., Rane A. Prostate cancer associated with CYP17 genotype. Pharmacogenetics 1999, 9:635-639.
22. Cicek M.S., Conti D.V., Curran A., Neville P.J., Paris P.L., Casey G., et al. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 2004, 59:69-76.
23. Salam M.T., Ursin G., Skinner E.C., Dessissa T., Reichardt J.K.V. Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol Semin Ori 2005, 23:246-253.
24. Mononen N., Seppaala E.H., Duggal P., Autio V., Ikonen T., Ellonen P., et al. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006, 66(2):743-747.
25. Paz-y-Mino C., Witte T., Robles P., Llumipanta W., Diaz M., Arevalo M. Association among polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population. Cancer Genet Cytogen 2009, 189:71-76.
26. Fan Y.S., Sasi R., Lee C. Localisation of the human CYP17 gene (cytochrome P45017(17alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics 1992, 14:1110-1111.
27. Kadonaga J.T., Jones K.A., Tjian R. Promotor-specific activation of RNA polymerase II transcription by SP1. Trends Biochem Sci 1986, 11:20-23.
28. Picado-Leonard J., Miller W.L. Cloning and sequence of the human gene for p450c17(steroid 17alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA 1987, 6:439-448.
29. Bergman-Jungestrom M., Gentile M., Lundin A.C., Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 1999, 84:350-353.
30. Feigelson H.S., Coetzee G.A., Kolonel L.N., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997, 57:1063-1065.
31. Haiman C.A., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Speizer F.E., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999, 59:1015-1020.
32. Carey A.H., Waterworth D., Patel K., White D., Little J., Novelli P., et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994, 3:1873-1876.
33. Diamanti-Kandarakis E., Bartzis M.I., Zapanti E.D., Spina G.G., Filandra F.A., Tsianateli T.C., et al. Polymorphism T→C (-34bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999, 71:431-435.
34. Gsur A., Bernhofer G., Hinteregger S., Haidinger G., Schatzl G., Madersbacher S., et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer 2000, 87:434-437.
35. Haiman C.A., Stampfer M.J., Giovannucci E., Ma J., Decalo N.E., Kantoff P.W., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:743-748.
36. Stanford J.L., Noonan E.A., Iwasaki L., Kolb S., Chadwick R.B., Feng Z., et al. A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002, 11:243-247.
37. Ntais C., Polycarpou A., Ioannidis J.P. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003, 12:120-126.
38. Vesovic Z., Herkommer K., Vogel W., Paiss T., Maier C. Role of a CYP17 promoter polymorphism for familial prostate cancer risk in Germany. Anticancer Res 2005, 25:1303-1307.
39. Antognelli C., Mearini L., Talesa V.N., Giannantoni A., Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005, 63:240-251.
40. Yang J., Wu H.F., Zhang W., Gu M., Hua L.X., Sui Y.G., et al. Polymorphisms of metabolic enzyme genes, living habits and prostate cancer susceptibility. Front Biosci 2006, 11:2052-2060.
41. Okugi H., Nakazato H., Matsui H., Ohtake N., Nakata S., Suzuki K. Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population. Cancer Detect Prev 2006, 30:262-268.
42. Cussenot O., Azzouzi A.R., Nicolaiew N., Fromont G., Mangin P., Cormier L., et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol 2007, 25:3596-3602.
43. Sobti R.C., Onsory K., Al-Badran A.I., Kaur P., Watanabe M., Krishan A., et al. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol 2006, 25:287-294.
44. Sobti R.C., Gupta L., Singh S.K., Seth A., Kaur P., Thakur H. Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a north Indian population. Cancer Genet Cytogen 2008, 185:78-85.
45. Sarma A.V., Dunn R.L., Lange L.A., Ray A., Wang Y., Lange E.M., et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Prostate 2008, 68:296-305.
46. Taylor J.D., Holmas T.M., Swanson G.M. Descriptive epidemiology of prostate cancer in metropolitan Detroit. Cancer 1994, 73:1704-1707.
47. Gsur A. Genetic polymorphisms and prostate cancer risk. World J Urol 2004, 21:414-423.
48. Bott S.R.J., Arya M., Shergill I.S., Williamson M. Molecular changes in prostatic cancer. Surg Oncol 2005, 14:91-104.
49. Habuchi T., Liqing Z., Suzuki T., Sasaki R., Tsuchiya N., Tachiki H., et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res 2000, 60:5710-5713.
50. Schatzl G., Gsur A., Bernhofer G., Haidinger G., Hinteregger S., Vutuc C., et al. Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. Urology 2001, 57:567-572.
51. Lin C.C., Wu H.C., Chen W.C., Chen H.Y., Tsai F.J. CYP17 gene promoter allelic variant is not associated with prostate cancer. Urol Oncol 2003, 21:262-265.
52. Hamada A., Danesi R., Price D.K., Sissung T., Chau C., Venzon D., et al. Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology 2007, 70:217-220.
53. Onen I.H., Ekmekci A., Eroglu M., Polat F., Biri H. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol 2007, 26:100-107.
54. Gunes S., Bagci H., Sarikaya S., Bilen C.Y., Kara N. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia. DNA Cell Biol 2007, 26:873-878.
55. Latil A.G., Azzouzi R., Cancel G.S., Guillaume E.C., Cochan-Priollet B., Berthon P.L., et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001, 92:1130-1137.
56. Yamada Y., Watanabe M., Murata M., Yamanaka M., Kubota Y., Ito H., et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer 2001, 92:683-686.
57. Nam R.K., Zhang W.W., Trachtenberg J., Jewett M.A., Emami M., Vesprini D., et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003, 12:1429-1437.
58. Tigli H., Yazici H., Dalay N. CYP17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia. Res Commun Mol Pathol Pharmacol 2003, 113-114:307-314.
59. Madigan M.P., Gao Y.T., Deng J., Pfeiffer R.M., Chang B.L., Zheng S., et al. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 2003, 107:271-275.
60. Forrest M.S., Edwards S.M., Houlston R., Kote-Jarai Z., Key T., Allen N., et al. Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate Cancer Prostatic Dis 2005, 8:95-102.